Molecular stratifications, biomarker candidates and new therapeutic options in current medulloblastoma treatment approaches.

ABSTRACT: Medulloblastoma (MB) is the most common malignant childhood tumor of the brain. Multimodal treatment consisting of surgery, radiation therapy, and chemotherapy reduced cumulative incidence of late mortality but increased the incidence of subsequent neoplasms and severe, incapacitating chronic health conditions. Present treatment strategies fail to recognize heterogeneity within patients despite wide divergence in individual responses. The persistent mortality rates and serious side effects of non-targeted cytotoxic therapies indicate a need for more refined therapeutic approaches. Advanced genomic research has led to the accumulation of an enormous amount of genetic information and resulted in a consensus distinguishing four molecular subgroups, WNT-activated, SHH-activated, and Group 3 an

SUBMITTER: Menyhart O 

PROVIDER: S-EPMC7098941 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature